#USA #Ankeny #Proliant Health #AlbufreeDX #Albumin

Proliant Health & Biologicals Raises the Standards with AlbufreeDX

Proliant Health & Biologicals, a leader in the field of purified proteins, has recently announced the launch of AlbufreeDX, a recombinant human albumin (rHA) specifically designed to cater to the increasing demand for high-quality, animal-free ingredients used in various diagnostic and life science applications. With over 20 years of experience in manufacturing albumin, Proliant ensures that its products maintain a consistent quality and reliable supply across the globe.

Headquartered in Ankeny, Iowa, and boasting manufacturing facilities in both the United States and New Zealand, Proliant is committed to supporting its customers in biotechnology, diagnostics, and healthcare sectors. The company emphasizes the importance of albumin in these areas, highlighting its applications in stabilizing proteins, preventing unwanted surface binding, and enhancing the performance and reproducibility of assays.

As the diagnostics field evolves, the need for materials with exceptional consistency and purity has escalated to avoid any variability or signal interference. Traditional albumins derived from animals or humans often come with added complexity, such as regulatory burdens and traceability issues. Dr. Christopher Warner, VP of Research and Development at Proliant, pointed out that companies in the in vitro diagnostics (IVD) sector are shifting towards utilizing devices free from animal or human origins to streamline regulatory processes globally. AlbufreeDX effectively addresses this trend and facilitates compliance with regulations while supporting corporate commitments to Environmental, Social, and Governance (ESG) goals.

Manufactured through precision fermentation, AlbufreeDX is designed to deliver high purity and consistent performance, along with excellent reproducibility from batch to batch. This makes it suitable for a variety of applications including protein stabilization, surface blocking, reagent formulation, and the creation of reference standards. Notably, these applications are critical in environments where minimizing variability and effectively eliminating the risk of pathogens originating from animal sources is paramount.

Dr. Christopher Detzel, President and CEO, noted, "As our customers' requirements have evolved, so has our portfolio. AlbufreeDX represents a natural extension of our expertise, offering a reliable animal-free albumin alternative while ensuring the consistency and scale our customers expect."

The introduction of AlbufreeDX further strengthens Proliant’s life science offerings. Future expansions of their product line will include AlbufreeTX, aimed at cell culture, and AlbufreeCGT, specifically designed to support emerging cell and gene therapy workflows. This expansion underlines Proliant's commitment to innovation and meeting the demands of the rapidly changing biotech landscape.

For additional information and updates, interested parties can visit Proliant's official website. In a market that increasingly values sustainability and traceability, Proliant Health & Biologicals is poised to lead the charge with innovative, quality-driven solutions.

For media inquiries, please contact: [email protected]